CDX-1401 in Combination with Decitabine in Patients with MDS
Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia
Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Clinical Pearls:
- This trial is based on data that hypomethylating agents have shown to increase the expression of NY-ESO in patients with solid tumors
- NY-ESO is a cancer-testis antigen that is not expressed significantly in any other malignancies, but its expression goes up in patients with MDS after exposure to hypomethylating agents
- This study will evaluate the safety of the vaccine CDX-1401 when given in combination with decitabine
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
